Innovent Biologics (信达生物) IPO: Limited Upside Despite Strong Cornerstones (Part 3)
Innovent Biologics launched the institutional book building today and intends to raise USD 377 to USD 423 million, with an implied market...
419 Views
Innovent Biologics IPO Valuation: Surprisingly Grounded in Reality
Innovent Biologics Inc (1641475D HK) launched its Hong Kong IPO today. The mid-point of Innovent's IPO price range of HK$12.50-14.00 per share...
706 Views
ECM Weekly (13 October 2018) - Tencent Music Delays IPO
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
698 Views
Innovent Biologics (信达生物) IPO: Pricing the PD-1 and Biosimilars Competition (Part 2)
Innovent Biologics, a leading biologics company in China, is raising up to USD 500 million to list in Hong Kong. In our previous insight (link...
596 Views
Innovent Biologics IPO Preview: Limited Upside on China's PD-1 Drug Market Compared to BeiGene
Innovent Biologics Inc (1641475D HK) is the fourth pre-profit biotech firm to IPO in Hong Kong since Ascletis Pharma Inc (1672 HK), BeiGene Ltd...
701 Views